Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939187 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3ADRB1HTR2A | |
| SCHEMBL29327433 | 0.79 | HTR2A (0.43) | SLC6A4ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL7241254 | 0.79 | OPRM1 (0.54) | SLC6A2SLC6A4SLC6A3ADRB1KCNH2 | |
| SCHEMBL4940861 | 0.79 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3ADRB1KCNH2 | |
| SCHEMBL4934110 | 0.79 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3ADRB1KCNH2 | |
| SCHEMBL23777634 | 0.77 | HTR2A (0.50) | SLC6A4ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL25144858 | 0.77 | HTR2A (0.50) | SLC6A4ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL5631570 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3ADRB1HTR2A | |
| SCHEMBL5631575 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3ADRB1HTR2A | |
| SCHEMBL5632277 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3ADRB1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176856-A1 | Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-07-24 | — | — | US | claimed |
| US-20080176856-A1 | Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-07-24 | — | — | US | disclosed |
| EP-1761512-A1 | NOVEL ALKYL SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123707-A1 | NOVEL ALKYL SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176856-A1 | Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A4 4/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.